There was also benefit in terms of renal outcomes
Personalized GLP-1 plans guided by licensed clinicians Built-in follow-up care that adapts with your progress Treatment recommendations matched to your goals Proactive support around side effects and expectations One private place for messaging, tracking, and refills Discreet shipping with a cleaner online care journey Generic fixed plans that rarely change over time Little education or long-term care structure Basic intake followed by more fragmented steps Side effects handled more reactively than proactively Limited support after the prescription is written More friction, less clarity, and weaker continuity Kala lost 40 lbs Morgan lost 36 lbs Christopher lost 42 lbs Noelle lost 29 lbs 8 out of 10 members lose 14+ lbs in 90 days* Join members nationwide moving through onboarding, treatment, check-ins, and refill care with less friction and better visibility
Journal of the International Society of Sports Nutrition, 6(1), 13 Nelson, A
Eli Lilly and Company Eli Lilly is gaining significant market share with Tirzepatide (Zepbound), a dual GLP-1 and GIP receptor agonist showing superior weight loss and metabolic benefits
And Druckers work in the 1980s and 1990s helped pave the way for key diabetes drugs, like Ozempic